ACA Therapeutics is a clinical-stage biopharmaceutical company dedicated to resolving the fundamental drivers of cancer and chronic diseases. Unlike traditional models focused on lifelong symptom management, we utilize our proprietary Upstream-Midstream-Downstream (UMD) Framework to support more comprehensive, system-based therapeutic approaches.

Our mission is to develop accessible, high-impact therapies —accessible, high-potency therapies that target the root causes of illness. By leveraging repurposed science, we aim to drastically reduce drug costs and systemic toxicity, expanding access to effective treatments across broader patient populations, not just a privileged few.